Fibroblast growth factor 23 and the future of phosphorus management.

Published

Journal Article (Review)

PURPOSE OF REVIEW: To present emerging data on the role of fibroblast growth factor 23 (FGF23) in mineral metabolism and adverse outcomes in chronic kidney disease (CKD). RECENT FINDINGS: FGF23 regulates phosphorus and vitamin D metabolism. Its levels increase progressively beginning in early CKD, presumably as a physiological adaptation to maintain normal serum phosphate levels or normal phosphorus balance. FGF23 promotes phosphaturia and decreases production of calcitriol. Recent studies suggest that increased FGF23 is associated with mortality, left ventricular hypertrophy, endothelial dysfunction and progression of CKD. These results were consistently independent of serum phosphate levels. SUMMARY: FGF23 is emerging as a novel and exciting biomarker that may help identify which CKD patients might benefit most from aggressive management of disordered phosphorus metabolism. Future studies should determine whether increased FGF23 levels exert direct end-organ toxicity, such as in the heart, vessels and kidneys.

Full Text

Duke Authors

Cited Authors

  • Wolf, M

Published Date

  • November 2009

Published In

Volume / Issue

  • 18 / 6

Start / End Page

  • 463 - 468

PubMed ID

  • 19770756

Pubmed Central ID

  • 19770756

Electronic International Standard Serial Number (EISSN)

  • 1473-6543

Digital Object Identifier (DOI)

  • 10.1097/MNH.0b013e328331a8c8

Language

  • eng

Conference Location

  • England